prikaz prve stranice dokumenta Do the benefits of aspirin exceed the risk of major bleeds in patients treated for primary prevention of cerebrovascular and cardiovascular disease?
  Download
PDF 94.92 KB
Professional paper - Other
Do the benefits of aspirin exceed the risk of major bleeds in patients treated for primary prevention of cerebrovascular and cardiovascular disease?
Acta medica Croatica : Časopis Akademije medicinskih znanosti Hrvatske, 73 (2019), 1; 81-86. urn:nbn:hr:220:783113
Kes, Petar; Bašić Kes, Vanja

Institutional repository: Repository of the Sestre milosrdnice University Hospital Center

Cite this document

Kes, P. & Bašić Kes, V. (2019). Do the benefits of aspirin exceed the risk of major bleeds in patients treated for primary prevention of cerebrovascular and cardiovascular disease?. Acta medica Croatica : Časopis Akademije medicinskih znanosti Hrvatske, 73. (1), 81-86. Retrieved from https://urn.nsk.hr/urn:nbn:hr:220:783113

Kes, Petar and Vanja Bašić Kes. "Do the benefits of aspirin exceed the risk of major bleeds in patients treated for primary prevention of cerebrovascular and cardiovascular disease?." Acta medica Croatica : Časopis Akademije medicinskih znanosti Hrvatske, vol. 73, no. 1, 2019, pp. 81-86. https://urn.nsk.hr/urn:nbn:hr:220:783113

Kes, Petar and Vanja Bašić Kes. "Do the benefits of aspirin exceed the risk of major bleeds in patients treated for primary prevention of cerebrovascular and cardiovascular disease?." Acta medica Croatica : Časopis Akademije medicinskih znanosti Hrvatske 73, no. 1 (2019): 81-86. https://urn.nsk.hr/urn:nbn:hr:220:783113

Kes, P. and Bašić Kes, V. (2019) 'Do the benefits of aspirin exceed the risk of major bleeds in patients treated for primary prevention of cerebrovascular and cardiovascular disease?', Acta medica Croatica : Časopis Akademije medicinskih znanosti Hrvatske, 73(1), pp. 81-86. Available at: https://urn.nsk.hr/urn:nbn:hr:220:783113 (Accessed 05 November 2024)

Kes P, Bašić Kes V. Do the benefits of aspirin exceed the risk of major bleeds in patients treated for primary prevention of cerebrovascular and cardiovascular disease?. Acta medica Croatica : Časopis Akademije medicinskih znanosti Hrvatske [Internet]. 2019 [cited 2024 November 05];73(1):81-86. Available at: https://urn.nsk.hr/urn:nbn:hr:220:783113

P. Kes and V. Bašić Kes, "Do the benefits of aspirin exceed the risk of major bleeds in patients treated for primary prevention of cerebrovascular and cardiovascular disease?", Acta medica Croatica : Časopis Akademije medicinskih znanosti Hrvatske, vol. 73, no. 1, pp. 81-86, 2019. [Online]. Available at: https://urn.nsk.hr/urn:nbn:hr:220:783113. [Accessed: 05 November 2024]

Metadata
Title (english)Do the benefits of aspirin exceed the risk of major bleeds in patients treated for primary prevention of cerebrovascular and cardiovascular disease?
Title (croatian)Je li dobrobit od liječenja aspirinom u bolesnika koji ga uzimaju zbog primarne prevencije moždano- i srčanokrvožilnih bolesti veća od rizika krvarenja?
AuthorPetar Kes
AuthorVanja Bašić Kes
Author's institution(Sestre milosrdnice University Hospital Center)
Scientific / art field,
discipline and subdiscipline		BIOMEDICINE AND HEALTHCARE
Clinical Medical Sciences
Neurology
Abstract (english)
Daily aspirin use has long been heralded for its cardioprotective effects, particularly in at-risk individuals like those with diabetes mellitus. However, a signifi cant amount of research published in the last 5 years has called into question the benefits of aspirin for primary prevention of cardiovascular disease. Risk factors for gastrointestinal bleeding with aspirin use include higher dose and longer duration of use, history of gastrointestinal ulcers or upper gastrointestinal pain, bleeding disorders, renal failure, severe liver disease, and thrombocytopenia. Other factors that increase the risk of gastrointestinal or intracranial bleeding with low-dose aspirin use include concurrent anticoagulation or nonsteroidal anti-infl ammatory drug use, uncontrolled hypertension, male sex, and older age. Aspirin for primary cardiovascular disease prevention should be highly individualized, based on the benefi t-risk ratio assessment for the given patient.
Abstract (croatian)
Dnevna upotreba aspirina već je dugo poznata zbog svojih zaštitnih moždano- i srčanokrvožilnih učinaka, što je osobito izraženo u osoba s visokim rizikom (npr. osoba sa šećernom bolesti). Međutim, značajan broj istraživanja objavljenih u posljednjih pet godina dovodi u pitanje prednosti aspirina u primarnoj prevenciji moždano- i srčanokrvožilnih bolesti. Čimbenici rizika za krvarenje iz probavnog sustava uzrokovanog aspirinom uključuju veću dozu i dugotrajno uzimanje lijeka, anamnezu o ulkusnoj bolesti, bolnost u žličici, poremećaje zgrušavanja krvi, zatajenje bubrega, tešku bolest jetre i trombocitopeniju. Drugi čimbenici koji povećavaju rizik od krvarenja iz probavnog sustava ili moždano krvarenje u osoba koje uzimaju nisku dozu aspirina uključuju istodobnu uporabu antikoagulacijskih lijekova ili nesteroidnih protuupalnih lijekova, nekontroliranu hipertenziju, muški spol i stariju dob. Primarna prevencija moždano- i srčanokrvožilnih bolesti uzrokovanih aspirinom mora biti prilagođena svakom pojedinom bolesniku pri čemu treba uzeti u obzir omjer koristi i štete od uzimanja lijeka.
Keywords (english)
Keywords (croatian)
Languageenglish
Languagecroatian
Publication typeProfessional paper - Other
Publication statusPublished
Peer reviewPeer review
Publication versionPublished version
Journal titleActa medica Croatica : Časopis Akademije medicinskih znanosti Hrvatske
Numberingvol. 73, no. 1, pp. 81-86
p-ISSN1330-0164
e-ISSN1848-8897
URN:NBNurn:nbn:hr:220:783113
Publication2019
Document URLhttps://hrcak.srce.hr/218968
Type of resourceText
Access conditionsOpen access
Terms of useLicence In copyright icon
Created on2024-06-24 12:28:41